BSE · 506128
Parnax Lab Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-1 Cr — a -220% net margin, versus 26.2% the period before.
Shareholding
As of 2026-06-30
- Promoter72.3%
- Public27.7%
3,572 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.83× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #27 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,562 Cr | 423.85 | 22.06 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,434 Cr | 159.09 | 9.4 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,961 Cr | 114.27 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,264 Cr | 326.41 | 19.62 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,863 Cr | 116.76 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,767 Cr | 69.25 | 5.06 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,825 Cr | 109.73 | 4.56 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,757 Cr | 79.34 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,071 Cr | 165.62 | 6.51 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,836 Cr | 141.61 | 4.04 | 8.95% | 11.15% |
| Parnax Lab Ltd.(this company) | ₹163 Cr | 12.75 | 1.71 | 12.38% | 4.74% |
AI analysis
AI-generated · google/gemini-2.5-flashParnax Lab Ltd. is listed on the Indian markets with a market capitalization of Rs 170 Cr. The company reported a revenue of Rs 189.41 Cr and an EPS of Rs 11.14. The price-to-earnings ratio stands at 13.25, with a book value of Rs 82.83.
Positives
- +The company's profit margin is high at 474.4%.
- +Return on Equity (ROE) is 12.38%.
- +Return on Capital Employed (ROCE) is 12.15%.
Negatives
- −Promoter pledge stands at 9.41% of total promoter holding as of June 30, 2026.
- −Quarterly revenue in Mar 2026 dropped to Rs 69.63 Cr from Rs 189.41 Cr in Mar 2025.
- −The annual net profit experienced a significant decrease from Rs 11.5189 Cr in Mar 2025 to -0.55 Cr in Mar 2026.
- −No DII or FII shareholding is disclosed in the latest period (June 2026).
Financial Performance
Parnax Lab Ltd. recorded a revenue of Rs 189.41 Cr in Mar 2025. The net profit for the same period was Rs 11.5189 Cr, with an EPS of Rs 10.03. Quarterly revenue in Mar 2026 was Rs 69.63 Cr, generating a net profit of Rs 2.18 Cr.
Profitability & Returns
The company’s Return on Equity (ROE) is 12.38%, and Return on Capital Employed (ROCE) is 12.15%. The reported profit margin is 474.4%. The annual EBITDA for Mar 2025 was Rs 21.0649 Cr.
Balance Sheet
Parnax Lab Ltd. has a debt-to-equity ratio of 0.97. The book value per share is Rs 82.83. Further details regarding assets and liabilities are not provided in the available data.
Ownership & Pledges
As of June 30, 2026, promoter holding in Parnax Lab Ltd. stood at 72.2971%, while public shareholding was 27.7029%. There were no shares held by DIIs or FIIs. A total of 9.41% of promoter shares were pledged as of June 30, 2026. Specifically, Binoy Baiju Shah (28.53% held) and Mihir Prakash Shah (34.24% held) had 390,744 shares each pledged.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.